Top

Current Urology Reports

Published in:

01-12-2018 | Urothelial Cancer (S Daneshmand, Section Editor)

Current Clinical Trials in Non-muscle Invasive Bladder Cancer

Authors: Timo K. Nykopp, Jose Batista da Costa, Miles Mannas, Peter C. Black

Published in: Current Urology Reports | Issue 12/2018

Abstract

Purpose of Review

As our molecular understanding of bladder cancer continues to advance, more and more novel agents are entering clinical trials across the spectrum of bladder cancer stages. The clinical trial activity for non-muscle invasive bladder cancer (NMIBC) has been boosted further by the evolution of specific disease states that set more uniform inclusion criteria for clinical trial design. Here, we aimed to review the current clinical trials landscape in non-muscle invasive bladder cancer with respect to these disease states.

Recent Findings

Most active clinical trials focus on high-risk NMIBC in either the BCG-naïve or BCG-unresponsive setting. Strict criteria to define the disease state and a clear pathway to drug registration have encouraged trials for patients with BCG-unresponsive NMIBC. The most promising potential breakthroughs for BCG-naïve patients include alternative BCG strains, immune-priming with intradermal BCG vaccination, and systemic immune checkpoint blockade. The latter therapy is also being actively investigated in multiple trials in BCG-unresponsive NMIBC, along with novel viral agents such as INSTILADRIN (nadofaragene firadenovec) and targeted agents such as oportuzumab monatox.

Summary

After many years of relative stagnation, multiple new therapies currently under investigation in well-designed clinical trials appear poised for routine clinical implementation in the near future. These therapies should dramatically improve the outcome of patients with NMIBC. We can look forward to the challenges of biomarker-driven drug selection, optimal drug sequencing, and rational combination therapies.

Ferlay J, et al (2013) GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase. No. 11. In: Lyon, Fr Int Agency Res Cancer

Amin MB, Edge SB, Greene FL, et. al. AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2017.

Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström P-U, Choi W, et al. Bladder cancer. Lancet. 2016;388:2796–810.CrossRefPubMed

Sylvester RJ, van der Meijden APM, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466–77.CrossRefPubMed

Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Piñeiro L, Ojea A, et al. The EORTC tables overestimate the risk of recurrence and progression in patients with non–muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables. Eur Urol. 2011;60:423–30.CrossRefPubMed

Sylvester RJ, Oosterlinck W, Holmang S, Sydes MR, Birtle A, Gudjonsson S, et al. Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation? Eur Urol. 2016;69:231–44. https://doi.org/10.1016/j.eururo.2015.05.050.CrossRefPubMed

Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, et al. EAU guidelines on non–muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017;71:447–61. https://doi.org/10.1016/j.eururo.2016.05.041.CrossRefPubMed

• Kamat AM, Colombel M, Sundi D, Lamm D, Boehle A, Brausi M, et al. BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG. Nat Rev Urol. 2017;14:244–55 Review of treatment options after BCG failure. CrossRefPubMed

Cambier S, Sylvester RJ, Collette L, Gontero P, Brausi MA, van Andel G, et al. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non–muscle-invasive stage Ta–T1 urothelial bladder cancer patients treated with 1–3 years of maintenance bacillus Calmette-Guérin. Eur Urol. 2016;69:60–9.

10.

Dinney CPN, Greenberg RE, Steinberg GD. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin. Urol Oncol Semin Orig Investig. 2013;31:1635–42. https://doi.org/10.1016/j.urolonc.2012.04.010.CrossRef

11.

•• U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) (2018) BCG-unresponsive nonmuscle invasive bladder cancer: Developing Drugs and Biologics for Treatment Guidance for Industry. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM529600.pdf. The latest definition of BCG-unresponsive NMIBC and guidance for clinical trials by FDA.

12.

Brausi M, Oddens J, Sylvester R, et al. Side effects of bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol. 2014. https://doi.org/10.1016/j.eururo.2013.07.021.CrossRefPubMed

13.

Veeratterapillay R, Heer R, Johnson MI, Persad R, Bach C. High-risk non-muscle-invasive bladder cancer—therapy options during intravesical BCG shortage. Curr Urol Rep. 2016;17:68. https://doi.org/10.1007/s11934-016-0625-z.CrossRefPubMedPubMedCentral

14.

Tolley DA, Parmar MK, Grigor KM, et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol. 1996. https://doi.org/10.1016/S0022-5347(01)66226-8.CrossRefPubMed

15.

Solsona E, Iborra I, Ricós JV, Monrós JL, Casanova J, Dumont R. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup. J Urol. 1999;161:1120–3. https://doi.org/10.1016/S0022-5347(01)61606-9.CrossRefPubMed

16.

Bosschieter J, Nieuwenhuijzen JA, van Ginkel T, Vis AN, Witte B, Newling D, et al. Value of an immediate intravesical instillation of mitomycin C in patients with non–muscle-invasive bladder cancer: a prospective multicentre randomised study in 2243 patients. Eur Urol. 2017;73:226–32. https://doi.org/10.1016/j.eururo.2017.06.038.CrossRefPubMed

17.

Oosterlinck W, Kurth KH, Schröder F, Bultinck J, Hammond B, Sylvester R. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage ta, T1 Papillary Carcinom. J Urol. 1993;149:749–52.CrossRefPubMed

18.

Messing EM, Tangen CM, Lerner SP, Sahasrabudhe DM, Koppie TM, Wood DP Jr, et al. Effect of intravesical instillation of gemcitabine vs saline immediately following resection of suspected low-grade non–muscle-invasive bladder cancer on tumor recurrence. JAMA. 2018;319:1880–8.CrossRefPubMedPubMedCentral

19.

Mostafid H, Cresswell J, Griffiths L, Kelly J, Knight A, Catto J, et al. PD66-04 RESULTS OF CALIBER: a phase II randomised feasibility trial of chemoablation versus surgical management in low risk non-muscle invasive bladder cancer (NMIBC). J Urol. 2018;199:e14231.

20.

Phillips RM, Hendriks HR, Sweeney JB, Reddy G, Peters GJ. Efficacy, pharmacokinetic and pharmacodynamic evaluation of apaziquone in the treatment of non-muscle invasive bladder cancer. Expert Opin Drug Metab Toxicol. 2017;13:783–91. https://doi.org/10.1080/17425255.2017.1341490.CrossRefPubMed

21.

Karsh L, Shore N, Saltzstein D, Bhat G, Reddy G, Allen LF, et al. PD11-07 integrated results of two multicenter, randomized, placebo controlled, double blind, phase 3 trials (SPI-611/612) of single-dose intravesical apaziquone immediately following resection in patients with non-muscle invasive bladder cancer. J Urol. 2016;195:e290.CrossRef

22.

Witjes F, Karsh L, Soloway M, Bhat G, Reddy G, Yang A, et al. MP13-07 improved efficacy of adjuvant, single dose intravesical apaziquone by timing post-resection in two double-blind, randomized, placebo-controlled phase 3 studies in non-muscle invasive bladder cancer. J Urol. 2016;195:e136–7.CrossRef

23.

Rentsch CA, Birkhäuser FD, Biot C, Gsponer JR, Bisiaux A, Wetterauer C, et al. Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. Eur Urol. 2014;66:677–88.CrossRefPubMed

24.

Meeks JJ, Lerner SP, Svatek RS. Bacillus Calmette-Guérin manufacturing and SWOG S1602 intergroup clinical trial. J Urol. 2017;197:538–40.CrossRefPubMed

25.

Biot C, Rentsch CA, Gsponer JR, Birkhauser FD, Jusforgues-Saklani H, Lemaitre F, et al. Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer. Sci Transl Med. 2012;4:137ra72.CrossRefPubMed

26.

Steinberg GD, Shore N, Karsh L, Bailen J, Woods M, Schoenberg M, et al. A phase I/II study of vesigenurtacel-l (hs-410) or placebo in combination with bacillus Calmette-Guérin (BCG) in patients with non-muscle invasive bladder cancer (NMIBC). J Immunother Cancer. 2014;2:P81.CrossRefPubMedCentral

27.

Steinberg GD, Shore ND, Karsh LI, Bailen JL, Bivalacqua T, Chamie K, et al. Immune response results from vesigenurtacel-l (HS-410) in combination with BCG from a randomized phase 2 trial in patients with non-muscle invasive bladder cancer (NMIBC). J Clin Oncol. 2017;35:4531.CrossRef

28.

Siefker-Radtke AO, Apolo AB, Bivalacqua TJ, Spiess PE, Black PC. Immunotherapy with checkpoint blockade in the treatment of urothelial carcinoma. J Urol. 2018;199:1129–42.CrossRefPubMed

29.

Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515:558–62.CrossRefPubMed

30.

Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387:1909–20.CrossRefPubMedPubMedCentral

31.

Balar AV, Castellano D, O’Donnell PH, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;18:1483–92.CrossRefPubMed

32.

Jarow JP, Lerner SP, Kluetz PG, Liu K, Sridhara R, Bajorin D, et al. Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association Public Workshop. Urology. 2014;83:262–5.CrossRefPubMed

33.

McKiernan JM, Masson P, Murphy AM, Goetzl M, Olsson CA, Petrylak DP, et al. Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy. J Clin Oncol. 2006;24:3075–80.CrossRefPubMed

34.

Barlow LJ, McKiernan JM, Benson MC. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy. J Urol. 2013;189:834–9. https://doi.org/10.1016/j.juro.2012.10.068.CrossRefPubMed

35.

Milbar N, Kates M, Chappidi MR, Pederzoli F, Yoshida T, Sankin A, et al. Oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer. Bladder Cancer. 2017;3:293–303.CrossRefPubMedPubMedCentral

36.

van Valenberg H, Colombo R, Witjes F. Intravesical radiofrequency-induced hyperthermia combined with chemotherapy for non-muscle-invasive bladder cancer. Int J Hyperth. 2016;32:351–62. https://doi.org/10.3109/02656736.2016.1140232.CrossRef

37.

Ayres B, Sri D, Perry M, Issa R. 5-year outcomes of RITE thermochemotherapy for BCG unresponsive high risk non muscle invasive bladder cancer. Eur Urol Suppl. 2017;16:e1158.CrossRef

38.

Kamat AM, Bellmunt J, Choueiri TK, Nam K, de Santis M, Dreicer R, et al. KEYNOTE-057: phase 2 study of pembrolizumab for patients (pts) with bacillus Calmette Guerin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC). J Clin Oncol. 2016;34:–TPS4576.CrossRef

39.

Black PC, Catherine T, Lerner SP, McConkey DJ, Lucia MS, Woods M, et al. S1605: phase II trial of atezolizumab in BCG-unresponsive nonmuscle invasive bladder cancer. J Clin Oncol. 2018;36:–TPS527.CrossRef

40.

Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J Immunol. 2014;192:5451–8. https://doi.org/10.4049/jimmunol.1490019.CrossRefPubMed

41.

Lee S, Margolin K. Cytokines in cancer immunotherapy. Cancers (Basel). 2011;3:3856–93.CrossRef

42.

Sonpavde G, Rosser CJ, Pan CX, Parikh RA, Nix J, Gingrich JR, Hernandez L, Huang BY, Wong HC. Phase I trial of ALT-801, a first-in-class T-cell receptor (TCR)-interleukin (IL)-2 fusion molecule, plus gemcitabine (G) for Bacillus Calmette Guerin (BCG)-resistant non-muscle-invasive bladder cancer (NMIBC). J Clin Oncol. 2015;33:15_suppl, e15509.

43.

Rhode PR, Egan JO, Xu W, Hong H, Webb GM, Chen X, et al. Comparison of the superagonist complex, ALT-803, to IL15 as cancer immunotherapeutics in animal models. Cancer Immunol Res. 2016;4:49–60. https://doi.org/10.1158/2326-6066.CIR-15-0093-T.CrossRefPubMed

44.

Huang J, Schisler J, Wong HC, Rosser CJ, Sterbis J. Intravesical ALT-803 for BCG-unresponsive bladder cancer – a case report. Urol Case Reports. 2017;14:15–7. https://doi.org/10.1016/j.eucr.2017.04.015.CrossRef

45.

Chamie K, Salmasi A, Rosser CJ, Rock A, Ferguson L, Wong HC. A multicenter clinical trial of intravesical BCG in combination with ALT-803 in patients with BCG-unresponsive non-muscle invasive bladder cancer. J Clin Oncol. 2018;36:–TPS544.CrossRef

46.

Gulley JL, Arlen PM, Tsang K-Y, Yokokawa J, Palena C, Poole DJ, et al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res. 2008;14:3060–9. https://doi.org/10.1158/1078-0432.CCR-08-0126.CrossRefPubMedPubMedCentral

47.

Gengenbacher M, Nieuwenhuizen N, Kaufmann S. BCG — old workhorse, new skills. Curr Opin Immunol. 2017;47:8–16.CrossRefPubMed

48.

Rentsch C, Bosshard P, Mayor G, Rieken M, Püschel H, Wirth G, et al. Results of the phase-I open-label clinical trial SAKK 06/14 assessing safety of intravesical instillation of the recombinant BCG VPM1002BC in patients with non-muscle invasive bladder cancer and previous failure to conventional BCG therapy. Eur Urol Suppl. 2018;17:e1050.CrossRef

49.

Yamashita M, Rosser CJ, Zhou JH, Zhang XQ, Connor RJ, Engler H, et al. Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer. Cancer Gene Ther. 2002;9:687–91. https://doi.org/10.1038/sj.cgt.7700488.CrossRefPubMed

50.

Tao Z, Connor RJ, Ashoori F, Dinney CPN, Munsell M, Philopena JA, et al. Efficacy of a single intravesical treatment with Ad-IFN/Syn 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation. Cancer Gene Ther. 2005;13:125.CrossRef

51.

Dinney CPN, Fisher MB, Navai N, O'Donnell MA, Cutler D, Abraham A, et al. Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer. J Urol. 2013;190:850–6.CrossRefPubMedPubMedCentral

52.

Navai N, Benedict WF, Zhang G, Abraham A, Ainslie N, Shah JB, et al. Phase 1b trial to evaluate tissue response to a second dose of intravesical recombinant adenoviral interferon α2b formulated in Syn3 for failures of bacillus Calmette–Guerin (BCG) therapy in nonmuscle invasive bladder cancer. Ann Surg Oncol. 2016;23:4110–4. https://doi.org/10.1245/s10434-016-5300-6.CrossRefPubMedPubMedCentral

53.

• Shore ND, Boorjian SA, Canter DJ, et al. Intravesical rAd–IFNα/Syn3 for patients with high-grade, bacillus Calmette-Guerin–refractory or relapsed non–muscle-invasive bladder cancer: a phase II randomized study. J Clin Oncol. 2017;35:3410–6 Results of the phase II trial with intravesical rAd-IFNα/Syn3 showing promising efficacy for patients with BCG-unresponsive NMIBC. CrossRefPubMedPubMedCentral

54.

Ramesh N, Ge Y, Ennist DL, Zhu M, Mina M, Ganesh S, et al. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor - armed oncolytic adenovirus for the treatment of bladder cancer. Clin Cancer Res. 2006;12:305–13. https://doi.org/10.1158/1078-0432.CCR-05-1059.CrossRefPubMed

55.

Burke JM, Lamm DL, Meng MV, Nemunaitis JJ, Stephenson JJ, Arseneau JC, et al. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J Urol. 2012;188:2391–7. https://doi.org/10.1016/j.juro.2012.07.097.CrossRefPubMed

56.

Packiam VT, Lamm DL, Barocas DA, Trainer A, Fand B, Davis RL III, et al. An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non-muscle-invasive bladder cancer: interim results. Urol Oncol Semin Orig Investig. 2017;36:440–7. https://doi.org/10.1016/j.urolonc.2017.07.005.CrossRef

57.

Kohlhapp FJ, Kaufman HL. Molecular pathways: mechanism of action for talimogene laherparepvec, a new oncolytic virus immunotherapy. Clin Cancer Res. 2016;22:1048–54. https://doi.org/10.1158/1078-0432.CCR-15-2667.CrossRefPubMed

58.

Andtbacka RHI, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33:2780–8. https://doi.org/10.1200/JCO.2014.58.3377.CrossRefPubMed

59.

Di Paolo C, Willuda J, Kubetzko S, Lauffer I, Tschudi D, Waibel R, et al. A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity. Clin Cancer Res. 2003;9:2837–48.PubMed

60.

Kowalski M, Guindon J, Brazas L, Moore C, Entwistle J, Cizeau J, et al. A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guérin. J Urol. 2012;188:1712–8.CrossRefPubMed

61.

Dickstein R, Wu N, Cowan B, Dunshee C, Franks M, Wolk F, et al. LBA27 phase 3 study of Vicinium in BCG-unresponsive non-muscle invasive bladder cancer: initial results. J Urol. 2018;199:e1167.CrossRef

62.

Dillon RL, Chooniedass S, Premsukh A, MacDonald G, Cizeau J, Adams GA. Abstract 614: VB4-845 tumor cell killing in a combination study with the anti-PD-1, Nivolumab. Cancer Res. 2017;77:614.CrossRef

63.

Hedegaard J, Lamy P, Nordentoft I, Algaba F, Høyer S, Ulhøi BP, et al. Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Cancer Cell. 2016;30:27–42. https://doi.org/10.1016/j.ccell.2016.05.004.CrossRefPubMed

64.

Robertson AG, Kim J, Al-Ahmadie H, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171:540–556.e25.CrossRefPubMedPubMedCentral

65.

Guagnano V, Kauffmann A, Wöhrle S, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective Pan-FGFR inhibitor. Cancer Discov. 2012;2:1118–33.CrossRefPubMed

66.

Nogova L, Sequist LV, Perez Garcia JM, et al. Evaluation of BGJ398, a fibroblast growth factor receptor 1-3 kinase inhibitor, in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors: results of a global phase I, dose-escalation and dose-expansion Stu. J Clin Oncol. 2016;35:157–65.CrossRefPubMedPubMedCentral

67.

Seager CM, Puzio-Kuter AM, Patel T, Jain S, Cordon-Cardo C, Mc Kiernan J, et al. Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer. Cancer Prev Res. 2009;2:1008–14.CrossRef

68.

McKiernan JM, Lascano D, Ahn J, Ghandour R, Pak JS, RoyChoudhury A, et al. A phase I/II multi-center study of intravesical nanoparticle albumin-bound rapamycin (ABI-009) in the treatment of BCG refractory non-muscle invasive bladder cancer. J Clin Oncol. 2015;33:TPS4576.

69.

Patel HD, Ball MW, Cohen JE, Kates M, Pierorazio PM, Allaf ME. Morbidity of urological surgical procedures: an analysis of rates, risk factors, and outcomes. Urology. 2015;85:552–60.CrossRefPubMed

70.

Thompson J. New NCCN guidelines: recognition and management of immunotherapy-related toxicity. J Natl Compr Cancer Netw. 2018;16:594–6.CrossRef

71.

Denzinger S, Fritsche H-M, Otto W, Blana A, Wieland W-F, Burger M. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach? Eur Urol. 2008;53:146–52.CrossRefPubMed

72.

Oughton JB, Poad H, Twiddy M, et al. Radical cystectomy (bladder removal) against intravesical BCG immunotherapy for high-risk non-muscle invasive bladder cancer (BRAVO): a protocol for a randomised controlled feasibility study. BMJ Open. 2017;7:e017913.PubMedPubMedCentral

Title: Current Clinical Trials in Non-muscle Invasive Bladder Cancer
Authors: Timo K. Nykopp
Jose Batista da Costa
Miles Mannas
Peter C. Black
Publication date: 01-12-2018
Publisher: Springer US
Published in: Current Urology Reports / Issue 12/2018
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI: https://doi.org/10.1007/s11934-018-0852-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Current Clinical Trials in Non-muscle Invasive Bladder Cancer

Abstract

Purpose of Review

Recent Findings

Summary

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 12/2018

Molecular Imaging for Evaluation of Viable Testicular Cancer Nodal Metastases

Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions

Use of Dynamic MRI of the Pelvic Floor in the Assessment of Anterior Compartment Disorders

Bladder Preservation Therapy: Review of Literature and Future Directions of Trimodal Therapy

Patient Distress in Women with Recurrent Urinary Tract Infections: How Can Physicians Better Meet Patients Needs?

Patient-Centered Outcomes in Bladder Cancer